EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers

Thilo Gambichler iD, Jan Späth, Shayda Said, Christina H Scheel, Laura Susok, Rene Stranzenbach

Journal of Clinical Apheresis · 2022-08 · 37 (4) · 360-366

DOI: 10.1002/jca.21982 ↗

At a glance

Journal article in Journal of Clinical Apheresis, published online on 2022-03-30. Written by Thilo Gambichler and 5 co-authors. Institution: Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany. Major MEDLINE topics: Mycosis Fungoides, Photopheresis, Skin Neoplasms. Cited 8 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Systemic immune‐inflammatory biomarkers (SIIBs) have not been studied in mycosis fungoides (MF) patients undergoing extracorporeal photopheresis (ECP).

Objective

The objective was to determine whether recently proposed SIIBs are suitable to predict ECP treatment outcome and overall prognosis of patients with MF.

Methods

Twenty‐nine MF patients were retrospectively evaluated who had undergone ECP. SIIBs included neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, lymphocyte‐to‐monocyte ratio, and pan‐immune‐inflammation value.

Results

Lymphocyte count ( P = .021), CD4+/CD8+ cells ( P = .00006), CD4+/CD56+ NK cells ( P = .00008), and LDH levels ( P = .0041) significantly declined after 6‐month ECP. We could not detect significant cutoff values for baseline SIIBs capable of predicting advanced disease, overall response to 6‐month ECP, or 5‐year lymphoma‐specific (LS) survival ( P > .05). Circulating baseline counts of CD4+/CD7‐ cells (cutoff: ≤ 12.2; P = .010) and CD4+/CD26‐ cells (cutoff: ≤ 19.5; P < .0001) significantly predicted ECP treatment response after 6 months. Moreover, CD4+/CD8+ ratio (cutoff: > 1.34; P = .045) and increased thrombocyte counts (cutoff: >259 000; P = .010) were baseline predictors for 5‐year LS death.

Conclusion

ECP appears to be beneficial in early‐stage CTCL as well. Lower percentages of circulating CD4+/CD7‐ and CD4+/CD26‐ lymphocytes at baseline correlate with response to ECP. In this study, however, baseline SIIBs did not appear to serve as suitable biomarkers for the prediction of treatment outcome and LS survival.

Subjects

MeSH terms (MEDLINE)

Mycosis FungoidesPhotopheresisSkin NeoplasmsBiomarkersHumansRetrospective Studies

Substances

Biomarkers

Authors and institutions

  • Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

ORCID profiles: Thilo Gambichler

Cite

APA

Gambichler, T., Späth, J., Said, S., Scheel, C. H., Susok, L., & Stranzenbach, R. (2022). Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers. Journal of Clinical Apheresis, 37(4), 360-366. https://doi.org/10.1002/jca.21982

Vancouver

Gambichler T, Späth J, Said S, Scheel CH, Susok L, Stranzenbach R. Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers. Journal of Clinical Apheresis. 2022;37(4):360-366. doi:10.1002/jca.21982

BibTeX
@article{Gambichler2022,
  author = {Gambichler, Thilo and Späth, Jan and Said, Shayda and Scheel, Christina H and Susok, Laura and Stranzenbach, Rene},
  title = {Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers},
  journal = {Journal of Clinical Apheresis},
  year = {2022},
  volume = {37},
  number = {4},
  pages = {360--366},
  doi = {10.1002/jca.21982}
}
Start for free →